Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFRY ALAN JACQMEIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1588624761
CMS profile
117341
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$193.80

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $193.80 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $126.08 1
AstraZeneca Pharmaceuticals LP $67.72 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFRY ALAN JACQMEIN

NPI 1588624761 · CMS profile ID 117341

Allopathic & Osteopathic Physicians / Family Medicine

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $193.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $126.0811/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141579567 CMS
AstraZeneca Pharmaceuticals LP $67.7205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105715512 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $193.80 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,267,086.60 104
PY2024 Recipient $1,250.00 1
PY2024 Principal investigator $2,152,633.93 77
PY2023 Recipient $1,250.00 1
PY2023 Principal investigator $2,337,900.80 1,040
PY2022 Principal investigator $878,603.36 715
PY2021 Principal investigator $421,556.50 35
PY2020 Principal investigator $639,049.71 93
PY2019 Principal investigator $963,118.36 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $11,476.50 12/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147149025
Principal investigator 1 ModernaTX, Inc. $58.32 12/24/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147149017
Principal investigator 1 ModernaTX, Inc. $4,815.00 12/13/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147149015
Principal investigator 1 ModernaTX, Inc. $11,165.00 12/06/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148853
Principal investigator 1 ModernaTX, Inc. $513,541.30 11/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148995
Principal investigator 1 ModernaTX, Inc. $5,261.44 11/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148997
Principal investigator 1 ModernaTX, Inc. $42,181.50 11/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147149003
Principal investigator 1 ModernaTX, Inc. $32,057.94 11/25/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147149001
Recipient SANOFI PASTEUR INC. $1,250.00 11/18/2024 Covered Recipient Physician Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune Vaccine or MenACYW Conjugate Vaccine in Older Adults No dispute reported 06/30/2026 1128698100
Principal investigator 1 ModernaTX, Inc. $249.45 11/15/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148991
Principal investigator 1 ModernaTX, Inc. $118,042.02 10/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148961
Principal investigator 1 ModernaTX, Inc. $158.08 10/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148963
Principal investigator 1 ModernaTX, Inc. $2,934.98 10/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148965
Principal investigator 1 ModernaTX, Inc. $8,548.06 10/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148967
Principal investigator 1 ModernaTX, Inc. $1,257.82 10/23/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148985
Principal investigator 1 ModernaTX, Inc. $9,050.00 10/21/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148957
Principal investigator 1 ModernaTX, Inc. $199.56 10/21/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148959
Principal investigator 1 ModernaTX, Inc. $282.00 10/14/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148983
Principal investigator 1 ModernaTX, Inc. $9,050.00 10/10/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148979
Principal investigator 1 ModernaTX, Inc. $2,142.00 10/10/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148981
Principal investigator 1 ModernaTX, Inc. $3,000.00 10/09/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148971
Principal investigator 1 ModernaTX, Inc. $1,036.40 10/03/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148969
Principal investigator 1 ModernaTX, Inc. $35,465.62 10/01/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148823
Principal investigator 1 ModernaTX, Inc. $3,493.00 09/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148949
Principal investigator 1 ModernaTX, Inc. $2,630.72 09/25/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148945
Principal investigator 1 ModernaTX, Inc. $1,687.26 09/25/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148947
Principal investigator 1 ModernaTX, Inc. $4,000.00 09/20/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148943
Principal investigator 1 ModernaTX, Inc. $3,900.00 09/18/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148787
Principal investigator 1 ModernaTX, Inc. $50.00 09/18/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148789
Principal investigator 1 ModernaTX, Inc. $569.00 09/18/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148791
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/18/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148793
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/18/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148795
Principal investigator 1 ModernaTX, Inc. $2,630.72 09/18/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148941
Principal investigator 1 ModernaTX, Inc. $9,000.00 09/04/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148935
Principal investigator 1 ModernaTX, Inc. $38,000.35 09/02/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148939
Principal investigator 1 ModernaTX, Inc. $15,104.06 08/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148933
Principal investigator 1 ModernaTX, Inc. $598.68 08/20/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147148931
Principal investigator 1 Novavax Inc $5,883.65 08/01/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123376837
Principal investigator 1 Novavax Inc $5,771.25 07/30/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123377385
Principal investigator 1 ModernaTX, Inc. $9,635.88 07/29/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148871
Principal investigator 1 ModernaTX, Inc. $19,271.76 07/12/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148869
Principal investigator 1 ModernaTX, Inc. $47,360.88 06/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148923
Principal investigator 1 ModernaTX, Inc. $144,607.45 06/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148927
Principal investigator 1 ModernaTX, Inc. $17,032.64 06/26/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148717
Principal investigator 1 ModernaTX, Inc. $4,056.00 06/20/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148925
Principal investigator 1 ModernaTX, Inc. $167.50 06/10/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148921
Principal investigator 1 ModernaTX, Inc. $4,510.56 05/29/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148915
Principal investigator 1 Novavax Inc $7,360.00 05/29/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) No dispute reported 06/30/2026 1123375167
Principal investigator 1 ModernaTX, Inc. $6,466.50 05/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147148913
Principal investigator 1 ModernaTX, Inc. $128,801.91 05/27/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148919
Principal investigator 1 SANOFI PASTEUR INC. $1,350.00 05/10/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune Vaccine or MenACYW Conjugate Vaccine in Older Adults No dispute reported 06/30/2026 1128698214
Principal investigator 1 ModernaTX, Inc. $33.50 05/07/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148917
Principal investigator 1 ModernaTX, Inc. $10,131.79 05/01/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147148911
Principal investigator 1 ModernaTX, Inc. $5,550.00 04/10/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147148907
Principal investigator 1 ModernaTX, Inc. $33.50 04/04/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148909
Principal investigator 1 Biogen, Inc. $23,296.00 04/03/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1104838211
Principal investigator 1 ModernaTX, Inc. $3,871.73 03/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148901
Principal investigator 1 ModernaTX, Inc. $8,111.18 03/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148905
Principal investigator 1 ModernaTX, Inc. $68,379.08 03/21/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147148893
Principal investigator 1 ModernaTX, Inc. $23,958.69 03/21/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148899
Principal investigator 1 ModernaTX, Inc. $118,451.66 03/21/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148903
Principal investigator 1 ModernaTX, Inc. $6,695.00 03/20/2024 Non-covered Recipient Entity
Encore Research Group-Jacksonville Center for Clinical Resea
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147182843
Principal investigator 1 ModernaTX, Inc. $20,115.00 03/08/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147148887
Principal investigator 1 Bavarian Nordic A/S $300.00 03/07/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1119664421
Principal investigator 1 ModernaTX, Inc. $11,094.99 02/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147148875
Principal investigator 1 ModernaTX, Inc. $235,392.94 02/28/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148885
Principal investigator 1 ModernaTX, Inc. $5,954.71 02/26/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148881
Principal investigator 1 ModernaTX, Inc. $164,263.23 02/14/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148605
Principal investigator 1 ModernaTX, Inc. $36,276.79 02/01/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148883
Principal investigator 1 ModernaTX, Inc. $33.50 01/26/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1147148867
Principal investigator 1 ModernaTX, Inc. $1,589.95 01/16/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147148865
Principal investigator 1 ModernaTX, Inc. $3,252.00 01/10/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148581
Principal investigator 1 ModernaTX, Inc. $9,100.00 01/10/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147148583
Principal investigator 1 Bavarian Nordic A/S $5,700.00 01/01/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1119664239
Principal investigator 1 Bavarian Nordic A/S $1,806.25 01/01/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1119664241
Principal investigator 1 Bavarian Nordic A/S $500.00 01/01/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1119664417
Principal investigator 1 Bavarian Nordic A/S $25,099.00 01/01/2024 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1119664419
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $64,730.68 01/01/2024 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy No dispute reported 06/30/2026 1095481338